Joerg Hasford

Q: What Schools Are Affiliated With Joerg Hasford

Joerg Hasford is affiliated with the following schools: University of Cologne, Ludwig Maximilian University of Munich, Heidelberg University

Joerg Hasford's AcademicInfluence.com Rankings

Joerg Hasford

Medical

#3531

World Rank

#4003

Historical Rank

Epidemiology

#712

World Rank

#742

Historical Rank

medical Degrees

Joerg Hasford

Mathematics

#7884

World Rank

#10705

Historical Rank

Statistics

#1017

World Rank

#1116

Historical Rank

Measure Theory

#2765

World Rank

#3303

Historical Rank

mathematics Degrees

Download Badge

Medical
Mathematics

Joerg Hasford's Degrees

Doctorate Medicine University of Cologne

Why Is Joerg Hasford Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Joerg Hasford is a German physician, biometrician, and epidemiologist. He is emeritus professor in the Institute for Medical Informatics, Biometry and Epidemiology at Ludwig Maximilian University of Munich, chair of the Ethics Committee of the Physicians’ Chamber of the Free State of Bavaria, president of the Association of the Research Ethics Committees in Germany and a member of the Expert Group on Clinical Trials of the European Commission. He has been influential in the study of safety of drugs and pharmacoepidemiology. He was one of the first biostatisticians to look at reliably compiled drug dosing history data in light of pharmacometric consequences. He is the namesake of the Hasford Score, a prognostic score for chronic myeloid leukemia.

(See a Problem?)

Joerg Hasford's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. (2006) (833)
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. (1998) (759)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa (2005) (592)
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. (2004) (564)
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. (1994) (454)
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. (2011) (409)
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) (2012) (401)
The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies. (2005) (328)
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. (2001) (322)
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. (2011) (315)
Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study (2002) (275)
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. (2014) (269)
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. (2011) (262)
Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. (1997) (222)
The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect (2006) (217)
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia (2016) (215)
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV (2015) (213)
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. (1993) (211)
Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. (2002) (209)
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. (2010) (208)
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants (2017) (189)
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries (2015) (171)
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. (2015) (153)
Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. (2015) (151)
Epidemiology of chronic myeloid leukaemia (CML). (2009) (136)
Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. (2012) (133)
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib (2014) (123)
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. (2004) (120)
Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. (1998) (118)
Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations (2011) (116)
Drug prescription in pregnancy: analysis of a large statutory sickness fund population (2004) (115)
Adverse drug reaction monitoring--cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions. (1997) (114)
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study (2012) (114)
A population-based European cohort study of persistence in newly diagnosed hypertensive patients (2002) (113)
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. (2007) (113)
Drug-related admissions and hospital-acquired adverse drug events in Germany: a longitudinal analysis from 2003 to 2007 of ICD-10-coded routine data (2011) (99)
Self-Medication with Over-the-Counter and Prescribed Drugs Causing Adverse-Drug-Reaction-Related Hospital Admissions: Results of a Prospective, Long-Term Multi-Centre Study (2014) (99)
Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. (2006) (96)
Evaluating quality-of-life measures for clinical trials in Germany. (1991) (91)
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib (2014) (89)
Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment – a review (2009) (89)
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. (1999) (88)
Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea (2003) (84)
Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany (2009) (81)
Adverse drug reaction monitoring—cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission (1997) (78)
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry (2017) (78)
Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. (2012) (76)
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies (2005) (74)
A prospective randomized comparison of unsedated ultrathin versus standard esophagogastroduodenoscopy in routine outpatient gastroenterology practice: does it work better through the nose? (2003) (72)
Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries (2017) (68)
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis (2012) (66)
Costs of adverse drug events in German hospitals--a microcosting study. (2012) (64)
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV (2016) (63)
Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study (2007) (62)
Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. (2014) (62)
Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia (2008) (62)
Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia (2011) (62)
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia – prospective long-term results from a randomized-controlled trial (2003) (61)
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML (2015) (61)
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV (2013) (57)
Persistence with asthma treatment is low in Germany especially for controller medication – a population based study of 483 051 patients (2010) (56)
Bridging Differences in Outcomes of Pharmacoepidemiological Studies: Design and First Results of the PROTECT Project (2014) (56)
Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score (1997) (55)
Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy. (2003) (49)
Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund population (2006) (49)
Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: Design of the LPSG trial (1991) (48)
Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol (2019) (46)
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment (2015) (45)
Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. (2007) (43)
Quality Assessment in Multiple Sclerosis Therapy (QUASIMS) (2007) (41)
Compliance and the Benefit/Risk Relationship of Antihypertensive Treatment (1992) (40)
Excess mortality in patients with asthma on long-acting β2-agonists (2006) (39)
Antiepileptic Drugs and Suicide: A Systematic Review of Adverse Effects (2014) (38)
Identification of adverse drug events: the use of ICD-10 coded diagnoses in routine hospital data. (2010) (37)
Adverse drug reaction monitoring--cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. (1997) (36)
Preventable ADRs leading to hospitalization — results of a long-term prospective safety study with 6,427 ADR cases focusing on elderly patients (2018) (35)
Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed. (2010) (33)
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib (2017) (33)
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia (2020) (33)
Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV. (2009) (32)
Analysis and validation of prognostic factors for CML. German CML Study Group. (1996) (32)
Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha [letter] (1996) (31)
A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia (2012) (31)
First results from an intensified monitoring system to estimate drug related hospital admissions. (2001) (31)
Roferon (rIFN-α2a) Is More Immunogenic Than Intron A (rIFN-α2b) in Patients with Chronic Myelogenous Leukemia (1994) (29)
Low-dose aspirin versus anticoagulants for prevention of coronary graft occlusion. (1990) (28)
In-hospital fall-risk screening in 4,735 geriatric patients from the LUCAS project (2012) (28)
Tolerability of β‐blockers metabolized via cytochrome P450 2D6 is sex‐dependent (2006) (28)
A naturalistic cohort study on effectiveness, safety and usage pattern of an over-the-counter nicotine patch (2003) (28)
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV (2018) (27)
Analysis and validation of prognostic factors for CML (1996) (27)
Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta‐analysis of three randomized trials (2000) (26)
The PEGASUS project--a prospective cohort study for the investigation of drug use in pregnancy. PEGASUS Study Group. (1997) (26)
High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (25)
Company observational post-marketing studies: drug risk assessment and drug research in special populations – a study-based analysis (1998) (24)
The impact of health care settings on survival time of patients with chronic myeloid leukemia. (2014) (23)
Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death (2015) (23)
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase (2014) (23)
Safety and usage pattern of low-dose diclofenac when used as an over-the-counter medication: results of an observational cohort study in a community-based pharmacy setting. (2004) (23)
Prevention of neural tube defects: effect of an intervention aimed at implementing the official recommendations (2003) (22)
Drug use assessment and risk evaluation in pregnancy--the PEGASUS-project. (1997) (22)
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV (2014) (21)
24-hour blood pressure measurement in antihypertensive drug trials: data requirements and methods of analysis. (1992) (21)
Sources of European drug consumption data at a country level (2014) (20)
Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial (2021) (20)
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group. (1996) (20)
The European LeukemiaNet: achievements and perspectives (2011) (20)
How long will chronic myeloid leukemia patients treated with imatinib mesylate live? (2005) (19)
CART and logistic regression analyses of risk factors for first dose hypotension by an ACE-inhibitor. (1993) (18)
Injection of fibrin tissue adhesive versus laser photocoagulation in the treatment of high-risk bleeding peptic ulcers: a controlled randomized study. (1996) (18)
Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent. (2006) (18)
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin (2019) (18)
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV (2018) (18)
The safety of drugs for OTC use: what evidence is required for an NSAID switch? (2002) (17)
Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death (2017) (17)
The Lupus Plasmapheresis Study Group: rationale and updated interim report. (1996) (17)
Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV (2008) (16)
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. (2003) (16)
The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha. (2005) (16)
Inhaled beta-2-agonists/muscarinic antagonists and acute myocardial infarction in COPD patients. (2014) (15)
The association of psychosocial factors with nausea and vomiting during pregnancy. (2008) (15)
Evaluation of the usefulness of dimethicone and/or senna extract in improving the visualization of abdominal organs (1987) (15)
First dose hypotension with enalapril and prazosin in congestive heart failure. (1991) (15)
Erythropoietin-induced treatment costs in patients suffering from renal anemia - a comparison between biosimilar and originator drugs. (2014) (15)
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon α (2003) (15)
[Digoxin concentrations in plasma and tissue. A postmortal investigation (author's transl)]. (1979) (14)
Tiotropium Respimat(®) vs. HandiHaler(®): real-life usage and TIOSPIR trial generalizability. (2016) (14)
Prediction of Molecular Response of Chronic Phase CML Patients by the EUTOS Score: Results of the Randomized CML-Study IV, (2011) (14)
The EUTOS CML score aims to support clinical decision-making. (2012) (14)
Time Trends of Period Prevalence Rates of Patients with Inhaled Long-Acting Beta-2-Agonists-Containing Prescriptions: A European Comparative Database Study (2015) (14)
A compilation of research working groups on drug utilisation across Europe (2014) (13)
Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies. (2002) (13)
Bleeding complications and liver injuries during phenprocoumon treatment: a multicentre prospective observational study in internal medicine departments. (2013) (13)
Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients – a Follow-up Analysis of the German CML Study IV (2011) (13)
Magnesium pyridoxal 5-phosphate glutamate reduces hyperlipidaemia in patients with chronic renal insufficiency (2004) (13)
Utilisation and Off-Label Prescriptions of Respiratory Drugs in Children (2014) (13)
Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV (2008) (12)
Confirmation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) in An Independent Prospective Patient Cohort. (2009) (12)
Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia (2017) (12)
Human myocardium and plasma digoxin concentration in patients on long-term digoxin therapy. (1978) (12)
Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q). (2009) (12)
Randomized Comparison of Interferon-{alpha}, Hydroxyurea, and Busulfan in Chronic Myeloid Leukemia: Response to Kantarjian and Talpaz and to Tura and Baccarani (1995) (12)
Adverse drug events in hospitalized patients. (1997) (12)
Cytogenetic response to prior treatment with interferon-α is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia (2006) (11)
Redundant trials can be prevented, if the EU clinical trial regulation is applied duly (2020) (11)
Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study (2016) (11)
Blood draws up to 3% of blood volume in clinical trials are safe in children (2018) (11)
Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha. (1996) (11)
[Medical research ethics committees in the Federal Republic of Germany: establishment and integration into medical research]. (2019) (10)
Drug risk assessment: A case for large trials with lean protocols (1994) (10)
German Multicenter Study Group for Adult ALL (GMALL): recruitment in comparison to ALL incidence and its impact on study results (2002) (9)
[Suicide with beta-methyldigoxin (author's transl)]. (1978) (9)
Declining Public Health Burden of Digoxin Toxicity: Decreased Use or Safer Prescribing? (2009) (9)
A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction (2016) (9)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: Update on the Survival Outcome Following Allogeneic HSCT after Imatinib Failure; Results of the German CML Study IV (2008) (9)
Chronic myelogenous leukemia : recent developments in prognostic evaluation and chemotherapy (1992) (9)
Adverse drug reaction monitoring--digitoxin overdosage in the elderly. (2001) (9)
Prescribing patterns of anti-emetic drugs during pregnancy in Germany (2006) (9)
The German competence network ‘Acute and chronic leukemias’ (2004) (8)
Randomized Comparison of Primary Allogeneic Stem Cell Transplantation and Best Available Drug Treatment in Chronic Myeloid Leukemia. (2006) (8)
Medical registries represent vital patient interests and should not be dismantled by stricter regulation. (2012) (8)
Risk-benefit analyses of drugs: Fundamental considerations and requirements from the point of view of the biometrician. Problems in the assessment of the combination of trimethoprim with sulfamethoxazole (2005) (8)
Design and implementation of a common drug information database for a university hospital (2004) (8)
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia (2004) (7)
The prognostic significance of early molecular and cytogenetic response for long-term progression-free and overall survival in imatinib-treated chronic myeloid leukemia (CML). (2012) (7)
Drug‐Induced Blood Consumption: The Impact of Adverse Drug Reactions on Demand for Blood Components in German Departments of Internal Medicine (2012) (7)
Lenalidomide Treatment Is Not Related to AML Progression Risk but Is Associated with a Survival Benefit in RBC Transfusion-Dependent Patients with IPSS Low- or Int-1-Risk MDS with del5q: Results From a Comparative Study (2011) (7)
Superior CMR-Rates with Tolerability-Adapted Imatinib 800 Mg Vs. 400 Mg Vs. 400 Mg + IFN In CML: The Randomized German CML-Study IV (2010) (7)
Screening for asymptomatic β-cell autoimmunity in young children. (2019) (7)
[Hospital admission due to adverse drug events (ADE): an analysis of German routine hospital data of 2006]. (2011) (7)
Feasibility of Imatinib Combination Therapies in a Randomized Trial for Chronic Myeloid Leukemia: The German CML-Study IV - Pilot Phase. (2004) (7)
Standards for subgroup analyses are needed?--we couldn't agree more. (2011) (7)
Secondary Malignancies in CML Patients – Data From the German CML Study IV (2012) (7)
[Psychopharmacological drug treatment in Munich nursing homes]. (2006) (6)
Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg {+/-} IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV. (2010) (6)
The Eutos Population-Based Registry : Evaluation of Baseline Characteristics and First Treatment Choices Of 2983 Newly Diagnosed Chronic Myeloid Leukemia (Cml) Patients from 20 European Countries (2014) (6)
Molecular Response <1% BCR-ABL IS at 12 Months Is Associated with Improved Overall and Progression-Free Survival. the Randomized German CML-Study IV (2010) (6)
Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study (2018) (6)
Comorbidity, Measured By The Charlson Index, Has No Negative Impact On Remission In Patients With Chronic Myeloid Leukemia: Results Of The Randomized CML-Study IV (2013) (6)
[Analysis of hospital admissions associated with digitalis glycosides]. (2007) (6)
[Advantages and problems of multicenter therapy studies exemplified by a study of the treatment of metastasizing renal cell carcinoma with recombinant interferon-alpha-2c]. (1987) (6)
An intranet database for a university hospital drug information center. (2001) (6)
Beneficial clinical effect of very early enalapril treatment in patients with acute left ventricular failure complicating myocardial infarction (1995) (6)
Correct use of non-indexed eGFR for drug dosing and renal drug-related problems at hospital admission (2020) (6)
Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial (2015) (6)
Optimizing Early Prediction Of Outcome In CML Using The Exact Decline Of BCR-ABL Transcript Levels Within 3 Months Of Imatinib Treatment As a Prognostic Marker (2013) (5)
A Simulation Study Using Validated Prognostic Factors to Assess Expected Long-term Survival (2005) (5)
Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV (2012) (5)
A multi-state model approach for prediction in chronic myeloid leukaemia (2014) (5)
Implementation of the EU clinical trial regulation transforms the ethics committee systems and endangers ethical standards (2020) (5)
Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV. (2009) (5)
The long term outcome of the patients with chronic myeloid leukemia (CML) who have achieved complete cytogenetic response (CCgR) to interferon-alpha (IFN alpha). A collaborative European study of 317 cases. (2001) (5)
Current Concepts for Assessing the Drug Adverse event Relationship and their Problems (1982) (5)
Incidence, Comorbidity and Treatment Survey of Chronic Myeoloid Leukemia in Germany. (2007) (5)
Etiology and Epidemiology of Chronic Myeloid Leukemia (2013) (4)
In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time (2015) (4)
The Follicular Lymphoma International Prognostic Index (FLIPI) Predicts Treatment Outcome in Patients with Advanced Stage Follicular Lymphoma Treated Front-Line with Rituximab and the Combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP). (2005) (4)
Adverse Events (AE) Under Imatinib Treatment Over 10 Years: Results From 1501 Patients Of The Randomized CML-Study IV (2013) (4)
Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia (2014) (4)
[Ethical aspects of clinical trials in rare diseases]. (2017) (4)
European commission consultation on pharmacovigilance (2008) (4)
Impact of the COVID-19 pandemic on clinical trials with drugs (2020) (4)
Design and Analysis of Clinical Trials of Compliance (2002) (4)
Seasonal changes in prescribing of long-acting beta-2-agonists-containing drugs. (2015) (4)
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study Group. (1997) (4)
Epidemiology and Etiology of Chronic Myeloid Leukemia (2018) (4)
European leukemianet-integration of the leading national leukemia networks (CML, AML, ALL, CLL, MDS, CMPD) another interdisciplinary partner groups in Europe (2007) (4)
Concept, Feasibility and Results of the Randomized Comparison of Imatinib Combination Therapies for Chronic Myeloid Leukemia: The German CML-Study IV. (2005) (4)
Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia. (1994) (3)
Implementation of a renal pharmacist consultant service — Information sharing in paper versus digital form (2021) (3)
Comparing the Prognostic Significance of Early Predictors of Survival in Chronic Myeloid Leukemia (CML) Treated with Imatinib - an Analysis of the Randomized CML-Study IV (2014) (3)
Large Simple Double-Blind Randomized Trials for the Rapid Assessment of the Effectiveness of COVID-19 Vaccines (2020) (3)
Incidence of CML in Europe -- a Comparison of 19 European Countries with US SEER Data (2014) (3)
The association of psychosocial factors with nausea and vomiting during pregnancy (2008) (3)
Age- and Gender-Specific Incidence of Hospitalisation for Digoxin Intoxication (2007) (3)
Benefit assessment in Germany. (2010) (3)
Reply to H. Kantarjian et al. (2014) (3)
CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry (2013) (3)
The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia (2015) (3)
Systematic Review and Meta-Analysis of Randomized Trials Comparing Imatinib 400 Mg/d Vs. Imatinib 800 Mg/d, and Imatinib 400 Mg/d Vs. Second Generation TKIs in Chronic Phase CML-Patients (2015) (3)
[Effect of optimized integrated management on long-term effectiveness of cardiologic rehabilitation]. (2000) (3)
Time-Related Interpretation of Molecular Response Levels According to Long Term Overall and Progression-Free Survival of CML Patients on First-Line Imatinib Treatment (2011) (3)
Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population‐based study (2019) (3)
Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomized trial (2020) (2)
Renal and hepatic tolerance of nonionic and ionic contrast media in intravenous digital subtraction angiography. (1989) (2)
Hass J, Firzlaff M (2005). Twenty‐four‐month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®). European Journal of Neurology 12:425–431 (2005) (2)
Cross-trial networking in AML: a step forward rather than corner cutting. (2004) (2)
Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials (2014) (2)
Impact of Balanced or Unbalanced Karyotype At Diagnosis On Prognosis of CML: Long-Term Observation From 1346 Patients of the Randomized CML Study IV (2012) (2)
Evolution of Blast Crisis (BC) in Chronic Myeloid Leukemia (CML) in the Imatinib-Era: A Rare Event with High Proportions of Low Risk Patients and of Early Bc; Need for Rapid Detection. Results of the German CML Study IV. (2009) (2)
ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10-YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV (2017) (2)
Major route additional chromosomal aberrations (ACA) precede increase of blasts in chronic myeloid leukemia (CML) independent of therapy. An analysis of CML studies III, IIIA and IV (2016) (2)
Therapy with Imatinib In Elderly CML Patients (>65years): Results of the German CML-Study IV. (2010) (2)
Rheumatology trials: selection of adequate response variables and their evaluation. (1984) (2)
Drug‐related hospital admissions: A prospective case‐based study (2003) (2)
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (2)
Effect of dose-optimized imatinib (IM) 800 mg on deep molecular responses (CMR 4.5) and prediction of survival: Results from the randomized CML-study IV. (2013) (2)
Drug-Related Hospital Admissions with Digitalis Glycosides (2006) (2)
CHOP Improves Response Rates but Not Overall Survival in Follicular and Mantle Cell Lymphoma (MCL)- Results of a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG ). (2004) (2)
Second Line Therapy with Second Generation TKI After Intolerance to Imatinib Based Treatments Showed High Overall Survival in Contrast to Second Line Therapy After Resistance; Results of the Randomized CML Study IV (2011) (2)
management and outcome of Cml-blast crisis: Results from the randomized Cml study Iv : V907 (2014) (2)
Prognostic Factors Identified Via a Cox Proportional Hazard Cure Model Explain Survival Differences After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myeloid Leukemia (CML) Between Two Consecutive Patient Cohorts (2012) (1)
Nilotinib vs. nilotinib plus interferon a induction and nilotinib or interferon a maintenance therapy for newly diagnosed BCR-ABL positive chronic myeloid leukemia patients in chronic phase: interim analysis of the TIGER (CML V) study (2017) (1)
[Quality and Structure of Outpatient Care for Adults with ADHD (Attention Deficit Hyperactivity Disorder) - Results of the RAABE-Study [Retrospective Data Analysis of ADHD Treatment in Adults]]. (2019) (1)
Erratum to: Ethical aspects of clinical trials in rare diseases (2017) (1)
High-Dose Oral Insulin in Young Children at High Risk for Type 1 Diabetes: The Pre-POInT-early Clinical Trial (2020) (1)
A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction (2016) (1)
Chronic myelogenous leukemia: progress in chemotherapy and evaluation of prognostic score 1. The German CML Study Group. (1993) (1)
A population based registry in chronic myeloid leukemia (CML), a network of registries covering "representative" areas or regions of Europe (l 10 millions people) (2010) (1)
Elderly CML Patients On Early Applied High Dose Imatinib Achieve Molecular Remissions As Fast As Younger Patients In Contrast To Patients On Standard Dose Imatinib: A Subanalysis Of The German CML-Study IV (2013) (1)
Impact of Variant t(9;22) and Additional Cytogenetic Aberrations at Diagnosis on Prognosis of CML (2010) (1)
Impact of Clinical Trials on Medical Practice: Problems and Consequences for Research Designs (1984) (1)
Prognosis and prognostic factors for patients with chronic myeloid leukemia (2003) (1)
[Chance or exploitation? Clinical studies from various views]. (2002) (1)
New European Union regulation of clinical trials puts trial participants at risk (2013) (1)
In memoriam: Ronald D. Mann, MD, FRCP, FRCGP, FFPM, FISPE, Professor Emeritus, Honorary Lifetime ISPE Fellow, 1928–2013 (2014) (1)
Equivalence of BCR-ABL Transcript Levels <1% According to the International Scale with Complete Cytogenetic Response in Chronic Phase CML Patients. (2012) (1)
EUROPEAN SUB-REGISTRY OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS (PTS) IN FAILURE AFTER IMATINIB THERAPY (IFP): RATIONALE, STUDY DESIGN AND CURRENT STATUS. A STUDY FROM THE EUROPEAN LEUKEMIANET (ELN) (2010) (1)
10-year survival with imatinib: final evaluation of randomized CML-study (2017) (1)
Clinical Trials Underestimate Age of Chronic Myeloid Leukemia (CML) Patients: Epidemiological Study in a Representative Area in Germany. (2007) (1)
Pretreatment Expression Levels of MDR1 and OCT-1 Predict Response to First Line Imatinib Treatment In Chronic Phase CML Patients (2010) (1)
Regional reporting of adverse drug reactions: a new computer-based network. (1999) (1)
Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry (2015) (1)
Drug Monitoring of Psychiatric Patients: Methodological Aspects (1985) (1)
PHP8 ADVERSE DRUG REACTIONS IN GERMANY: COST ANALYSIS OF INTERNAL MEDICINE HOSPITALIZATIONS (2008) (1)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with a Related Donor in Chronic Myeloid Leukemia (CML): An Explanation for Fast Improvement of Survival in Two Consecutive German CML Studies. (2009) (1)
Defining Therapy Goals for Major Molecular Remission in Chronic Myeloid Leukemia: Results of the Randomized CML-Study IV (2014) (1)
[Clinical research at the European LeukemiaNet]. (2006) (1)
Use long acting β2 agonists only when asthma cannot be controlled otherwise (2013) (1)
Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure. (1991) (1)
In-hospital falls and potentially inappropriate medication (PIM) (2013) (1)
Distinct Characteristics of e13a2 versus e14a2 BCR-ABL Chronic Myeloid Leukemia under Upfront Treatment with Imatinib – an Analysis of the German CML Study IV, (2011) (1)
Concept and feasibility of the randomized comparison of imatinib with imatinib combination therapies for chronic myeloid leukemia: The German CML Study IV - Pilot Phase (2005) (1)
ANALYSIS OF TREATMENT AND OUTCOME DATA OF 2904 PATIENTS FROM THE EUTOS POPULATION-BASED REGISTRY (2015) (1)
The Eutos Population Based Registry - Incidences of CML Across Europe (2014) (1)
Outcome and Prognosis of 1955 Patients with Chronic Myeloid Leukemia: First Results of the CML-Registry of the European Treatment and Outcome Study EUTOS. (2009) (1)
A25 The prognostic profile of the patients is essential for any comparative interpretation of clinical trials (1996) (0)
PREVENTION OF CORONARY VEIN GRAFT OCCLUSION: LOW-DOSE ACETYLSALICYLIC ACID VERSUS COUMARIN (ASAAC - STUDY) (1987) (0)
The Impact Of Balanced and Unbalanced Karyotypes On Prognosis Of CML: From Chronic Phase To Blast Crisis (2013) (0)
Smoking Is a Prognostic Factor for Survival in Chronic Myeloid Leukemia (2015) (0)
Psychological impact on parents by participating in the Pre-POINT study (2015) (0)
Safety of Beta-Blockers Metabolised Via CYP2D6 is Sex-Dependent (2006) (0)
responders : a study of complete cytogenetic α Chronic myeloid leukemia and interferon- (2013) (0)
Discontinued at Least 90 Days Before the Procedure Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Interferon-? Before Allogeneic Bone Marrow Transplantation in Chronic (2013) (0)
No more transplantation in CML? Authors' reply (2007) (0)
[Publication of clinical studies. CONSORT statement]. (2002) (0)
The Pattern Of Cytogenetic Aberrations In CML BC Stratified For Treatment (2013) (0)
Clinical trials: increasing value, reducing waste - the potential role of ethics committees (2017) (0)
Comment on “Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed” Haematologica 2011;96(12):1779–82 (2012) (0)
Similar outcome of different treatment strategies in patients 16 to 60 years of age with acute myeloid leukemia (AML) (2008) (0)
Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA (2015) (0)
P-101 Influence of WHO categories and gender on the prognosis of MDS del(5q) patients (2013) (0)
Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry (2011) (0)
59FALL-RISK FACTORS' PREVALENCE IN HOSPITALISED PATIENTS AND PERFORMANCE OF THE LUCAS FALL-RISK SCREENING (2014) (0)
prospective randomized trial of the European MCL Network prolongs progression-free survival in mantle-cell lymphoma : results of a autologous stem cell transplantation in first remission significantly Early consolidation by myeloablative radiochemotherapy followed (2005) (0)
Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death (2021) (0)
Impact of unbalanced karyotypes at diagnosis on prognosis of CML. (2015) (0)
[Critical evaluation of the new legal regulation of pharmaceutical trials with adults who lack decision-making capacity: a survey of human research ethics committees in Germany]. (2019) (0)
Chronic Myeloid Leukaemia Patients Treated In Teaching Hospitals Seem To Have a Survival Advantage Compared To Other Settings (2013) (0)
Burden of Disease/ Epidemiology of Illness (2014) (0)
Association between inhaled long-acting beta-2-agonists and the risk of acutemyocardial infarction: A methodological comparison of two databases (2014) (0)
German AML Intergroup (2004) (0)
Pitfalls in the evaluation of prognostic factors. (1987) (0)
Comparison of survival between patients with and without switch to second-line tyrosine kinase inhibitor in a trial on chronic myeloid leukaemia with randomisation to first-line imatinib (2016) (0)
Drug treatment or stem cell transplantation as primary treatment for patients with CML (2007) (0)
Monitoring Multizentrischer Therapiestudien (1988) (0)
[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias]. (2016) (0)
Time trends in prevalence of inhaled long-acting beta-2-adrenoceptor agonist prescribing-a comparison of seven european electronic health record databases (2013) (0)
Abstract Seventh Annual Meeting Society for Clinical Trials May 11–14, 1986 Hotel Meridien, Montreal, Quebec, CanadaInfluence of diagnostic certainty upon the results of a field trial (1986) (0)
Female and Elderly Chronic Myeloid Leukemia Patients Often Do Not Receive an Adequate TKI Treatment (2016) (0)
The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry. (2009) (0)
Absolute BCR-ABL Transcript Levels At 3 Months but Not At Diagnosis Predict Survival of Chronic Myeloid Leukemia (CML) Patients On Imatinib Therapy (2012) (0)
ADVERSE DRUG EVENTS IN HOSPITALIZED PATIENTS. AUTHORS' REPLIES (1997) (0)
20 Years of Adverse Drug Reaction Monitoring: A Review (1982) (0)
W6: THE APPROPRIATENESS OF COMMON MEDICAL DATA SOURCES: RANDOMIZED TRIALS, META-ANALYSES, EPIDEMIOLOGICAL AND OBSERVATIONAL STUDIES FOR PHARMACOECONOMIC ANALYSES (1999) (0)
The European Leukemia Net CML Registry - Objectives, Achievements and First Results. (2006) (0)
Archive (2005–1962) (2001) (0)
Putting the Pieces Together: Using “Off-The-Shelf” Software to Safely Transfer Medical Data (2001) (0)
·P-48 Biometric issues in measuring and analyzing compliance in clinical trials (1990) (0)
Research Ethics Committees: Adaptation to The New European Regulation of Clinical Trials – A Viewpoint From Germany (2015) (0)
Achievement Of a MR5.0 Within the Randomized CML-Study IV: Feasibility, Differences Between Treatment Arms, and Prognostic Implications (2013) (0)
Network German Low Grade Lymphoma Study Group ( GLSG ) and the European Mantle Cell Lymphoma (2007) (0)
High age and high frequency of treatment switch in CML patients outside of clinical trials: interim results of the German CML VI trial (2017) (0)
[Self-medication with nicotine preparations. 3 of 10 smokers renounce the blue fumes]. (2003) (0)
24-hour blood pressure measurement; methods of analysis and data requirements (1991) (0)
Effect of cytogenetics at diagnosis on outcome of CML: Results from the randomized German CML Study IV. (2011) (0)
Clinical trials and medical practice: Methodological considerations (1984) (0)
CML Study IV of CML: long-term observation of 1151 patients from the randomized Impact of additional cytogenetic aberrations at diagnosis on prognosis (2012) (0)
leukemia trials with interferon-alpha (letter) comparative analysis of the Italian and German chronic myeloid Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a (2013) (0)
Randomized , Double-Blind , Placebo-Controlled , Phase I 11 Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as Adjunct to Induction Treatment of High-Grade Malignant Non-Hodgkin ' s Lymphomas (2003) (0)
In MDS Del(5q), Factors Other Than Age and Sex Distribution Contribute to the Prognostic Advantage, Which Diminishes over Time (2014) (0)
cell lymphoma A new prognostic index (MIPI) for patients with advanced-stage mantle (2008) (0)
A19 Classification and regression trees as a tool to identify prognostic factors in long-term clinical trials (1993) (0)
LeukemiaNet: A transnational model for cooperative leukemia research. (2011) (0)
Erratum (2016) (0)
Remission status should not be treated as a base-line covariate – Reply to Etienne et al. (2014) (0)
Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation. (2008) (0)
PROSPECTIVE MULTICENTER STUDY FOR TREATMENT OF CHRONIC MYELOCYTIC-LEUKEMIA - COMPARISON OF BUSULFAN, HYDROCYUREA AND INTERFERON ALPHA (UPDATE APRIL, 1990) (1991) (0)
Dmg treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Commentary (2007) (0)
[Digoxin concentration in the myocardium and plasma in patients with long-term digitalis therapy]. (1978) (0)
Erratum (2016) (0)
Quantitative Assessment of the Impact of Interferon Alpha (IFN) vs. Busulfan vs. Hydroxyurea and of Risk Profile on Survival in Chronic Myelogenous Leukemia (CML) (1998) (0)
Assessment of Blood Products Demand in the Treatment of Adverse Drug Reactions in German Hospitals (2013) (0)
Sex-specific frequency of beta-blocker related hospitalization to internal and emergency departments (2006) (0)
Response: Drug treatment and allografting as first-line therapy in young patients with CML (2007) (0)
European Sub-Registry of Chronic Myelogenous Leukemia (CML) Patients (pts) in Failure after Imatinib Therapy (IFP): Rationale, Study Design and Current Enrollment. (2006) (0)
ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006 (2006) (0)
53A Randomize the first patient? Benefits and risks of adding a new treatment-arm to a longterm clinical trial (1995) (0)
How to study therapy dilemmas with respect to BMT (1993) (0)
Efficacy and safety of imatinib in CML over 10 years. (2014) (0)
Documentation and analysis of adverse event data in clinical trials: The German chronic myeloid leukemia study experience (1992) (0)
The impact of the German ALL/AUL-study on the treatment of acute leukemia (1986) (0)
Ten-year survival after randomized comparison of imatinib (IM) 400 mg vs. IM 800 mg vs. IM + IFN vs. IM + Ara C vs. IM after IFN in chronic myeloid leukemia (CML). (2017) (0)
Treatment and outcome of 2904 CML patients from the EUTOSpopulation-based registry (2017) (0)
ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006 (2006) (0)
Planning, conducting and evaluating multicenter clinical trials in Germany— The view of a biometric center (1984) (0)
[Can patent rights be an obstacle? Various views from clinical studies]. (2002) (0)
The Cytogenetic Profile In Lymphoid and Myeloid CML Blast Crisis (2013) (0)
Interferon-α in the Treatment of CML: Comparison of Busulfan versus Hydroxyurea versus Interferon-α (1994) (0)
A Two-Fold Rise of BCR-ABL Transcript Levels Advises BCR-ABL Mutation Analysis in Imatinib-Treated Chronic Myeloid Leukemia (CML) - an Analysis of the Randomized CML-Study IV (2014) (0)

This paper list is powered by the following services:

Other Resources About Joerg Hasford

en.wikipedia.org

What Schools Are Affiliated With Joerg Hasford?

Joerg Hasford is affiliated with the following schools:

Joerg Hasford's Academic­Influence.com Rankings

Joerg Hasford's Degrees

Why Is Joerg Hasford Influential?

Joerg Hasford's Published Works

Published Works

Other Resources About Joerg Hasford

What Schools Are Affiliated With Joerg Hasford?

Joerg Hasford's AcademicInfluence.com Rankings